It might seem axiomatic that PET imaging of ER with FES and PgR with FFNP in breast cancers, and AR with FDHT in prostate cancers, would be of use in detecting and staging disease and as prognostic and predictive factors in guiding optimal treatment for women and men with these cancers. The gene discussed is PGR; the disease is breast cancer.